|
|
|
Natera Inc (NASDAQ: NTRA) |
|
|
|
| |
Natera Inc Outlook |
On January 13 2025 the Natera Inc provided following guidance
nnNatera Inc. Provides Preliminary Financial Estimates for Q4 and Full Year 2024nn
AUSTIN, Texas—Natera, Inc. (NASDAQ: NTRA), a leading innovator in cell-free DNA and genetic testing, has released its preliminary unaudited results for the fourth quarter and the entirety of 2024. The company projects significant revenue growth, driven by its expanding portfolio and increased demand for its testing solutions.
For the fourth quarter of 2024, Natera anticipates total revenues of around $472 million. This figure marks a remarkable increase of approximately 52% compared to the $311 million reported in the same quarter of 2023. This growth underscores the company's strong performance and robust market position in the genetic testing landscape.
In terms of annual performance, Natera expects to achieve total revenues of about $1.7 billion for the full year 2024. This projection highlights Natera's ongoing momentum and commitment to advancing genetic testing technologies, reflecting the increasing acceptance and utilization of these services in both clinical and consumer markets.
Overall, these preliminary results demonstrate Natera's successful execution of its growth strategy and its ability to capitalize on the rising demand for innovative genetic and genomic testing solutions. The company remains focused on enhancing its offerings to further advance precision medicine and contribute to improved patient care outcomes.,
|
On January 9 2024 the Natera Inc provided following guidance
Natera Inc., a leading provider of cell-free DNA testing, has released preliminary revenue figures for the fourth quarter and full year ended December 31, 2023. The company anticipates total revenues of around $300 million for the fourth quarter of 2023, representing a significant 38% increase compared to $217 million in the same period of the previous year. Furthermore, Natera Inc. estimates total revenues of approximately $1.07 billion for the entire year of 2023, reflecting a notable 30% growth compared to the previous year. These optimistic revenue figures highlight the company's successful performance and its position as a global leader in the field of cell-free DNA testing.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
